UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY
Investment Company Act File number: 811-01528
Bruce Fund, Inc.
(Exact name of registrant as specified in charter)
__________________
20 North Wacker Drive, Suite 2414, Chicago, IL 60606
(Address of principal executive offices) (Zip code)
__________________
Robert B. Bruce
20 North Wacker Drive, Suite 2414
Chicago, Illinois 60606
(Name and address of agent for service)
Registrant's telephone number, including area code: 312-236-9160
Date of fiscal year end: June 30
Date of reporting period: 07/01/2021 - 06/30/2022
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (Secs. 239.24 and 274.5 of this chapter),to file reports with the Commission, not later than August 31 of each
year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b 1-4).The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget C'OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. Sec. 3507.
| Bruce Fund, Inc. | ||||||||
| Annual Proxy Report | ||||||||
| Report Period: July 1, 2021 to June 30, 2022 | ||||||||
| Security | Ticker | Cusip | Meeting | Proposed | Description | Vote | For, Against | For or Against |
| Name | Date | (M) or (S) | or Abstain | Management | ||||
| AT & T | T | 00206R102 | 5/18/2022 | M | Directors | Y | A | A |
| AT & T | T | 00206R102 | 5/18/2022 | M | Auditors | Y | F | F |
| AT & T | T | 00206R102 | 5/18/2022 | M | Executive Compensation | Y | A | A |
| AT & T | T | 00206R102 | 5/18/2022 | S | Scope 3 emissions | Y | A | F |
| AT & T | T | 00206R102 | 5/18/2022 | S | Compensation Program | Y | F | A |
| AT & T | T | 00206R102 | 5/18/2022 | S | Political Congruancy | Y | F | A |
| AT & T | T | 00206R102 | 5/18/2022 | S | Civil Rights Audit | Y | A | F |
| AT & T | T | 00206R102 | 5/18/2022 | S | Independent Chairman | Y | A | F |
| Supernus | SUPN | 868459108 | 6/16/2022 | M | Directors | Y | F | F |
| Supernus | SUPN | 868459108 | 6/16/2022 | M | Auditors | Y | F | F |
| Supernus | SUPN | 868459108 | 6/16/2022 | M | Executive Compensation | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | M | Directors | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | M | Accounting | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | M | Executive Compensation | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | S | Proxy access | Y | A | F |
| Apple | APPL | 037833100 | 2/23/2021 | S | Executive Compensation improve | Y | A | F |
| Newmont | NEM | 651639106 | 4/20/2022 | M | Directors | Y | F | F |
| Newmont | NEM | 651639106 | 4/20/2022 | M | Accounting | Y | F | F |
| Newmont | NEM | 651639106 | 4/20/2022 | M | Executive Compensation | Y | F | F |
| Mannkind | MNKD | 56400P706 | 5/9/2022 | M | Directors | Y | F | F |
| Mannkind | MNKD | 56400P706 | 5/9/2022 | M | Accounting | Y | F | F |
| Mannkind | MNKD | 56400P706 | 5/9/2022 | M | Executive Compensation | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/8/2022 | M | Directors | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/8/2022 | M | Accounting | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/8/2022 | M | Executive Compensation | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/8/2022 | M | Incentive Plan | Y | F | F |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Directors | Y | F | F |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Accounting | Y | F | F |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Executive Compensation | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/24/2022 | M | Directors | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/24/2022 | M | Accounting | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/24/2022 | M | Executive Compensation | Y | F | F |
| Merck | MRK | 58933Y105 | 5/23/2022 | M | Directors | Y | F | F |
| Merck | MRK | 58933Y105 | 5/23/2022 | M | Compensation | Y | F | F |
| Merck | MRK | 58933Y105 | 5/23/2022 | M | Accounting | Y | F | F |
| Merck | MRK | 58933Y105 | 5/23/2022 | S | Independent Chairman | Y | A | F |
| Merck | MRK | 58933Y105 | 5/23/2022 | S | Lobbying | Y | F | A |
| Merck | MRK | 58933Y105 | 5/23/2022 | S | Covid-19 access | Y | A | F |
| Chiasma | CHMA | 16706W102 | 8/2/2021 | M | Merger Agreement | Y | F | F |
| Chiasma | CHMA | 16706W102 | 8/2/2021 | M | Postpone Meeting | Y | F | F |
| Chiasma | CHMA | 16706W102 | 8/2/2021 | M | Executive Compensation | Y | F | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | M | Directors | Y | F | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | M | Accounting | Y | F | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | M | Executive Compensation | Y | F | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | S | Proxy access | Y | A | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | S | Political spending | Y | F | A |
| Pfizer | PFE | 717081103 | 4/27/2022 | S | Intelectual Property | Y | A | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | S | Board Oversight | Y | A | F |
| Pfizer | PFE | 717081103 | 4/27/2022 | S | Protecting Technology | Y | A | F |
| Nextera | NEE | 65339F101 | 5/18/2022 | M | Directors | Y | F | F |
| Nextera | NEE | 65339F101 | 5/18/2022 | M | Auditors | Y | F | F |
| Nextera | NEE | 65339F101 | 5/18/2022 | M | Compensation | Y | F | F |
| Nextera | NEE | 65339F101 | 5/18/2022 | S | Board Matrix | Y | A | F |
| Nextera | NEE | 65339F101 | 5/18/2022 | S | Diversity | Y | A | F |
| Allstate | ALL | 020002101 | 5/23/2022 | M | Directors | Y | F | F |
| Allstate | ALL | 020002101 | 5/23/2022 | M | Auditors | Y | F | F |
| Allstate | ALL | 020002101 | 5/23/2022 | M | Compensation | Y | F | F |
| Paratek Pharm. | PRTK | 699374302 | 6/7/2022 | M | Directors | Y | F | F |
| Paratek Pharm. | PRTK | 699374302 | 6/7/2022 | M | Auditors | Y | F | F |
| Bausch Health | BHC | 071734107 | 6/20/2022 | M | Directors | Y | F | F |
| Bausch Health | BHC | 071734107 | 6/20/2022 | M | Incentive Plan | Y | F | F |
| Bausch Health | BHC | 071734107 | 6/20/2022 | M | Auditors | Y | F | F |
| Bausch Health | BHC | 071734107 | 6/20/2022 | M | Compensation | Y | F | F |
| Viatris | VTRS | 92556V106 | 12/8/2021 | M | Directors | Y | F | F |
| Viatris | VTRS | 92556V106 | 12/8/2021 | M | Auditors | Y | F | F |
| Viatris | VTRS | 92556V106 | 12/8/2021 | M | Compensation | Y | F | F |
| Viatris | VTRS | 92556V106 | 12/8/2021 | M | Say on Pay Frequency | Y | 1 yr. | F |
| Amerco | UHAL | 023586100 | 8/18/2021 | M | Directors | Y | F | F |
| Amerco | UHAL | 023586100 | 8/18/2021 | M | Accounting | Y | F | F |
| Amerco | UHAL | 023586100 | 8/18/2021 | S | Board Actions | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | M | Directors | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | M | Auditors | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | M | Say on Pay | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | S | Independent Chair | Y | A | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | S | Termination Pay | Y | A | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | M | Supermajority elimination | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | S | Competition Practices | Y | A | F |
| Abbvie | ABBV | 00287Y109 | 5/5/2022 | S | Political Spending | Y | A | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Directors | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Auditors | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Compensation | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Long term Incentive Plan | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Distributable reserves | Y | F | F |
| Abbott | ABT | 002824100 | 4/28/2022 | M | Directors | Y | F | F |
| Abbott | ABT | 002824100 | 4/28/2022 | M | Say on Pay | Y | F | F |
| Abbott | ABT | 002824100 | 4/28/2022 | M | Accounting | Y | F | F |
| Abbott | ABT | 002824100 | 4/28/2022 | S | Lobbying Disclosure | Y | F | A |
| Abbott | ABT | 002824100 | 4/28/2022 | S | Special Meeting Threshold | Y | A | F |
| Abbott | ABT | 002824100 | 4/28/2022 | S | Rule 10b5-1 Plans | Y | A | F |
| Abbott | ABT | 002824100 | 4/28/2022 | S | Independent Chair | Y | A | F |
| Abbott | ABT | 002824100 | 4/28/2022 | S | Antimicrobial Report | Y | A | F |
| Sirius XM Holding | SIRI | 82968B103 | 6/1/2022 | M | Directors | Y | F | F |
| Sirius XM Holding | SIRI | 82968B103 | 6/1/2022 | M | Accounting | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/5/2022 | M | Directors | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/5/2022 | M | Auditors | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/5/2022 | M | Compensation | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/5/2022 | S | Special Meeting | Y | A | F |
| Avista | AVA | 05379B107 | 5/11/2022 | M | Directors | Y | F | F |
| Avista | AVA | 05379B107 | 5/11/2022 | M | Auditors | Y | F | F |
| Avista | AVA | 05379B107 | 5/11/2022 | M | Compensation | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Directors | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Auditors | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Equity Incentive | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Compensation | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/17/2022 | M | Directors | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/17/2022 | M | Auditors | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/17/2022 | M | Compensation | Y | F | F |
| IGM Biosciences | IGMS | 449585108 | 6/20/2022 | M | Directors | Y | F | F |
| IGM Biosciences | IGMS | 449585108 | 6/20/2022 | M | Auditors | Y | F | F |
| General Electric | GE | 369604103 | 5/3/2022 | M | Directors | Y | F | F |
| General Electric | GE | 369604103 | 5/3/2022 | M | Auditors | Y | F | F |
| General Electric | GE | 369604103 | 5/3/2022 | M | Compensation | Y | F | F |
| General Electric | GE | 369604103 | 5/3/2022 | M | Long-Term Incentive | Y | F | F |
| General Electric | GE | 369604103 | 5/3/2022 | S | Stock Options | Y | A | F |
| General Electric | GE | 369604103 | 5/3/2022 | S | Termination Pay | Y | A | F |
| General Electric | GE | 369604103 | 5/3/2022 | S | Employee Director | Y | A | F |
| CMS Energy | CMS | 125896100 | 5/5/2022 | M | Directors | Y | F | F |
| CMS Energy | CMS | 125896100 | 5/5/2022 | M | Auditors | Y | F | F |
| CMS Energy | CMS | 125896100 | 5/5/2022 | M | Compensation | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Auditors | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Board Report | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Allocation | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Compensation | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Amendment | Y | F | F |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Share Capital Increases | Y | A | A |
| EDAP | EDAP | 268311107 | 6/23/2022 | M | Employee Grants | Y | A | A |
| Amryt Pharma | AMYT | 03217L106 | 6/23/2022 | M | Directors | Y | F | F |
| Amryt Pharma | AMYT | 03217L106 | 6/23/2022 | M | Auditors | Y | F | F |
| Amryt Pharma | AMYT | 03217L106 | 6/23/2022 | M | Compensation | Y | F | F |
| Amryt Pharma | AMYT | 03217L106 | 6/23/2022 | M | Allot Shares | Y | F | F |
| Amryt Pharma | AMYT | 03217L106 | 6/23/2022 | M | Pre-Emption Rights | Y | F | F |
| Acorda Theraputics | ACOR | 00484M601 | 6/9/2022 | M | Directors | Y | F | F |
| Acorda Theraputics | ACOR | 00484M601 | 6/9/2022 | M | Auditors | Y | F | F |
| Acorda Theraputics | ACOR | 00484M601 | 6/9/2022 | M | Compensation | Y | F | F |
| Acorda Theraputics | ACOR | 00484M601 | 6/9/2022 | M | Share Increase | Y | F | F |
| Organon | OGN | 68622V106 | 6/6/2022 | M | Directors | Y | F | F |
| Organon | OGN | 68622V106 | 6/6/2022 | M | Auditors | Y | F | F |
| Organon | OGN | 68622V106 | 6/6/2022 | M | Compensation | Y | F | F |
| Organon | OGN | 68622V106 | 6/6/2022 | M | Frequency | Y | 1 yr. | F |
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Bruce Fund, Inc.
By: /s/ Robert B. Bruce
Robert B. Bruce, President
Date: 8/11/2022
